Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
The Cleveland Clinic
The Cleveland Clinic
Fred Hutchinson Cancer Center
Vanderbilt-Ingram Cancer Center
Mayo Clinic